Drugs / VX-708
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05518734 | Sep 2022 → Mar 2023 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05347394 | Apr 2022 → Apr 2023 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-708 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05518734 ↗ |
| Route | Intravenous | “Solution for intravenous (IV) administration.” NCT05518734 ↗ |